Investors Recordati In Brief Recordati is an established international pharmaceutical group engaged in the research, production and sale of pharmaceutical products with more than 4,300 employees listed on the Italian Stock Exchange since 1984. It is headquartered in Milan and has operations in Europe, Russia and other CIS countries, Ukraine. , Turkey, North Africa, United States of America, Canada, Mexico, some countries of South America, Japan and Australia. Recordati offers a wide range of innovative medicines, both original and licensed, belonging to different therapeutic areas and to the rare diseases sector. A network of pharmaceutical representatives and orphan drug representatives promotes its specialties in approximately 150 markets. The main products in the portfolio are drugs for the treatment of hypertension and other cardiovascular diseases, treatments for urological diseases such as benign prostatic hyperplasia and urinary incontinence, therapies for metabolic diseases and from 2019 an innovative antipsychotic drug for the treatment of schizophrenia. The products for the treatment of rare diseases are mainly aimed at the treatment of endocrinological and metabolic pathologies of genetic origin. Oriented towards innovation and the sale of highly specialized products, the Recordati Group is the European partner of well-known international pharmaceutical companies. Recordati focuses its research and development activities mainly in the area of rare diseases. The company also has six pharmaceutical production plants - in Italy (Milan), France (Montluçon), Turkey (Çerkezköy), Spain (Utebo - Zaragoza), Czech Republic (Padubice) and Tunisia (Ariana) - two of pharmaceutical chemical production - in Italy (Campoverde di Aprilia, Latina) and Ireland (Cork) - and one dedicated to the packaging and distribution of drugs for rare diseases in France (Nanterre). In addition to producing active ingredients for its original drugs, Recordati also produces and markets others for the international market. The Group pursues a model of sustainable growth, integrating social and environmental aspects into its strategy and business processes, with the awareness that long-term economic development cannot exist if we do not act responsibly. Main economic data • Consolidated revenues for the year 2020 amounted to € 1,448.9 million. • Operating profit is € 469.0 million in 2020. • Net profit for 2020 is € 355.0 million. Growth strategy • Expansion through organic growth and through acquisitions. • Strengthening of the presence in the main markets. • Increase of the product portfolio through the introduction of products in development and acquisitions into the pipeline. • Worldwide development of the activity dedicated to rare diseases. Annual balance Institutional Brochure The Prize Alert Service Italian | English Company data RECORDATI SpA VIA M. CIVITALI, 1 - 20148 MILAN, ITALY SHARE CAPITAL € 26,140,644.5 fully paid up REG. IMP. MILAN, MONZA, BRIANZA and LODI 00748210150 TAX CODE / P. VAT number 00748210150 REA MILANO 401832 Company Subject to the management and coordination of Rossini Luxembourg S.à rl delivered by Tech Style Site Services Alert service Legal notices Privacy Policy Latest news October 29, 2021 RECORDATI: PROGRAMMA DI ACQUISTO DI AZIONI PROPRIE A SERVIZIO DEI PIANI DI STOCK OPTION 28 ottobre 2021 RECORDATI: APPROVATI RISULTATI DEI PRIMI NOVE MESI DEL 2021. RICAVI +5,7%, EBITDA +2,1% E UTILE NETTO +8,1%. PROSEGUE LA RIPRESA INIZIATA NEL SECONDO TRIMESTRE